Clinical Trial Update: Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ixazomib-daratumumab without dexamethasone (IDara) in elderly patients with relapse-refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• ixazomib (ixazomib)

Snippet

Sponsor: University Hospital, Caen | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN